NasdaqGS:ALKSBiotechs
Why Alkermes (ALKS) Is Up 22.4% After Strong Phase 2 Narcolepsy Data For Alixorexton
Alkermes recently reported detailed positive phase 2 Vibrance-2 results for its oral orexin 2 receptor agonist alixorexton in adults with narcolepsy type 2, showing statistically significant, clinically meaningful gains in wakefulness and reduced daytime sleepiness versus placebo, with a generally well-tolerated safety profile across three once-daily doses.
By also improving fatigue and cognition scores and supporting the launch of a global phase 3 program, alixorexton is emerging as a...